The introduction of generic risperidone in Medicare Part D.

ABSTRACT:

Objectives

The introduction of generic second-generation antipsychotics (SGAs), starting with risperidone in July 2008, could reduce antipsychotic spending and cost-related use barriers. This study examines associations between generic risperidone use and spending and adherence after introduction among Medicare Advantage (MA) beneficiaries.

Study design

Historic cohort study.

Methods

The study included MA beneficiaries receiving SGA treatment prior to July 2008. We examined antipsychotic spending using linear models, adherence (proportion of days covered ≥ 80%) using logistic models, and nonpersistence (time to first gap in antipsychotic use > 30 days) in 2009 using Cox proportional hazard models, comparing beneficiaries with versus without generic use, adjusting for

SUBMITTER: Fung V 

PROVIDER: S-EPMC4915110 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature